The results of this paper showed that IL-6 expression levels were significantly higher in the breast cancer group compared to the benign breast tumor group, and serum IL-6 expression levels were significantly higher in patients with HER-2 (+) and triple negative breast cancer than in patients with HR (+). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.